Tokyo, Japan

Hirotaka Okabe


Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 10(Granted Patents)


Company Filing History:


Years Active: 2005

Loading Chart...
1 patent (USPTO):Explore Patents

Title: **Hirotaka Okabe: Innovator in Pharmaceutical Compounds**

Introduction

Hirotaka Okabe is an esteemed inventor based in Tokyo, Japan, renowned for his contributions to the field of pharmaceuticals. With a focus on innovative compounds, Okabe has made strides in medical research, particularly concerning treatments for diabetes and neurodegenerative diseases.

Latest Patents

Hirotaka Okabe holds a notable patent for "Dihydropyrazolopyridine compounds and pharmaceutical use thereof." This invention presents a unique set of dihydropyrazolopyridine compounds, which are represented by a specific chemical formula defined in the patent specification. These compounds demonstrate a selective and strong inhibitory activity on glycogen synthase kinase-3 beta (GSK-3β). The implications of this research suggest that such compounds could serve as valuable medicaments for preventing and treating diabetes, diabetic complications, neurodegenerative diseases, and even act as immunopotentiators.

Career Highlights

Okabe is employed at Mitsubishi Pharma Corporation, where he collaborates with like-minded professionals to advance pharmaceutical innovation. His single patent highlights his significant contribution to enhancing the medicinal landscape, showcasing his inventive capabilities.

Collaborations

Throughout his career, Hirotaka Okabe has worked alongside notable colleagues such as Toshiyuki Kohara and Kenji Fukunaga. These collaborations foster an environment of shared knowledge and expertise, further enhancing the potential for groundbreaking pharmaceutical developments.

Conclusion

Hirotaka Okabe exemplifies the spirit of innovation through his dedicated work in drug development and inventive research. His patent on dihydropyrazolopyridine compounds opens new avenues for treating chronic health conditions, marking him as a key figure in the pharmaceutical industry and contributing to advancements in medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…